CN113244288B - Traditional Chinese medicine composition and application thereof - Google Patents
Traditional Chinese medicine composition and application thereof Download PDFInfo
- Publication number
- CN113244288B CN113244288B CN202110543818.8A CN202110543818A CN113244288B CN 113244288 B CN113244288 B CN 113244288B CN 202110543818 A CN202110543818 A CN 202110543818A CN 113244288 B CN113244288 B CN 113244288B
- Authority
- CN
- China
- Prior art keywords
- parts
- myocardial
- chinese medicine
- traditional chinese
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
The invention provides a traditional Chinese medicine composition which is prepared from the following raw materials in parts by weight: 15 parts of fructus choerospondiatis, 10 parts of radix salviae miltiorrhizae, 10 parts of sandalwood, 10 parts of myrobalan and 10 parts of kapok. The medicinal composition is prepared from natural medicinal components, has an improvement effect on biochemical indexes such as glutathione peroxidase activity, superoxide dismutase content, malondialdehyde content and the like in blood and myocardial tissues of acute myocardial ischemia rats and myocardial necrosis area, and has the effects of resisting acute myocardial ischemia of the rats caused by ISO and treating coronary heart disease.
Description
Technical Field
The invention relates to the field of traditional Chinese medicines, in particular to a novel medicine formula for treating myocardial ischemia.
Background
Myocardial ischemia is a pathological condition in which the supply of blood flow to the heart is reduced, oxygen supply to the heart is reduced, myocardial metabolic disorder is caused, and the heart cannot normally perform physiological functions. Ischemic heart diseases include angina pectoris, myocardial infarction, coronary heart disease, etc., which are attracting wide attention worldwide because of their high prevalence and high mortality. Global disease burden (GBD) research results show that 1000 more than ten thousand new cases of ischemic heart disease worldwide in 2017, 1.2 million patients are found, and more than 800 million people die, which is the first cause of death in the global population. With the improvement of the economic level and the change of life style of residents in China, the prevalence rate and the death rate of ischemic heart diseases in China are continuously increased, nearly 150 thousands of people die of the ischemic heart diseases in 2015 all the country, and the disease is the second death reason of the residents in China which is second to cerebrovascular diseases.
At present, chemical medicines such as nitrates, statins blood fat reducing medicines, antiplatelet preparations and the like are mostly adopted for treating ischemic heart diseases, and no traditional Chinese medicine with exact curative effect is used for clinical treatment at present.
Disclosure of Invention
The invention aims to overcome the defects in the prior art, and seeks a traditional Chinese medicine formula with an exact curative effect on myocardial ischemia, so as to widen the medicine resources of ischemic heart diseases.
In order to achieve the purpose, the invention provides a traditional Chinese medicine composition which is prepared from the following raw materials in parts by weight: 15 parts of fructus choerospondiatis, 10 parts of radix salviae miltiorrhizae, 10 parts of sandalwood, 10 parts of myrobalan and 10 parts of kapok.
The invention also provides a pharmaceutical preparation containing the traditional Chinese medicine composition.
The medicinal preparation is in the form of pill, granule, capsule, aqua, etc.
The invention also provides application of the traditional Chinese medicine composition in preparing medicines for resisting myocardial ischemia and treating coronary heart disease.
Compared with the prior art, the invention has the following advantages:
1. the medicinal composition is prepared from natural medicinal components, has an improvement effect on biochemical indexes such as glutathione peroxidase activity, superoxide dismutase content, malondialdehyde content and the like in blood and myocardial tissues of acute myocardial ischemia rats and myocardial necrosis area, and has the effects of resisting acute myocardial ischemia of the rats caused by ISO and treating coronary heart disease.
2. The traditional Chinese medicine composition has the advantages of simple formula, wide raw material source, low cost and simple preparation.
Drawings
FIG. 1 is a comparison of pathological sections of rat myocardial tissue under different treatments.
Detailed Description
The present invention will be described in detail with reference to specific examples.
Example 1
The preparation example of the traditional Chinese medicine composition comprises the following steps:
weighing the following raw materials in parts by weight:
15 parts of fructus choerospondiatis, 10 parts of radix salviae miltiorrhizae, 10 parts of sandalwood, 10 parts of myrobalan and 10 parts of kapok.
Adding water and heating, reflux-extracting for 3 times, adding water 12 times the weight of the raw materials each time, extracting for 1.5h each time, mixing the extractive solutions, concentrating the extractive solution to relative density of 1.1-1.2, adding ethanol until the ethanol content in the solution is 85%, precipitating, and collecting the filtrate to obtain the aqueous extract of the Chinese medicinal composition.
Example 2
Application examples
1 Material
1.1 animal healthy SD rats with half of male and female, weight 200-250 g. Composed of black dragon
1.2 provided by GLP center of TCM university in Jiang, license number SCXK- (Jing) 2009-0001.
1.2 Instrument KY2000 semi-automatic biochemical analyzer (Shimadzu corporation, Japan); 756PC Spectrum UV Spectrophotometer (Shanghai spectrometer Co., Ltd.); BL-420F biological function experimental system.
1.3 reagent GSH-Px test kit (batch No. 20180626), SOD kit (batch No. 20181105), and MDA kit (batch No. 20171214), all purchased from Nanjing institute of bioengineering.
1.4 the drug isoproterenol hydrochloride (Shanghai Hefeng pharmaceuticals, Inc.); dioxin xuekang capsules (guoduo group ltd); example 1 an aqueous extract SXK of the Chinese medicinal composition of the present invention was prepared.
2 method
2.1 establishment of Isoprenyl (Iso) induced acute myocardial ischemia model: rats were randomly divided into a blank group, a model group, SXK high, medium and low 3 dose groups and a positive control drug (dioxemcon capsule), and SXK of an aqueous solution was administered in terms of body surface area according to normal administration doses, which were respectively a high, medium and low dose group: 4mL (after drying the Chinese medicinal composition prepared in the above example 1, the composition is prepared into high, medium and low three concentrations of 0.4g/mL, 0.2g/mL and 0.1g/mL with water as high, medium and low dose groups, and the gavage administration is carried out at 1mL/100 g), 4mL of positive control group (equivalent to 30 mg. kg. of Di' ao Xin Xuekang)-1). The blank and model groups were given the corresponding volume of distilled water and all rats were gavaged continuously for 15 days, 1 time/day. According to literature reports (influence of dihydroquercetin on the protective effect and the oxidative stress level of myocardial ischemia model rats, quality of things, lucidity, loyalty and the like, Shizhen Chinese medicine, 2019,30 (10): 2370-2372) and pre-test, from day 12, the rest groups except the blank group are 5 mg-kg-1The dose of (2) was i.p. injection of isoproterenol 1 times/day for 3 consecutive days.
2.2 detection index and method
2.2.1 electrocardiographic detection: after the last gavage, rats were anesthetized with 10% chloral hydrate by intraperitoneal injection (3 ml. kg)-1) After anaesthesia, the patient lies on the back and is fixed on an operating table, one side of a needle electrode is inserted into the subcutaneous skin of the four limbs of a rat, the other side of the needle electrode is connected with a BL-420F biological function experiment system, a standard II-lead electrocardiogram is recorded, the electrocardiogram change before and after modeling is observed, the voltage value of the J point of the electrocardiogram and the T wave change before and after modeling are compared, the T wave height measurement takes a P-R section as a base line, 5 continuous waveforms are measured, the average value of the waveforms is taken, and statistical analysis is carried out.
2.2.2 measurement of GSH-Px, SOD and MDA in serum: blood is taken from abdominal aorta of a rat through a cannula, a part of blood plasma is taken to separate blood serum, and the content of GSH-Px, SOD and MDA in the blood serum is measured according to the operation of a kit instruction.
2.2.3 preparation of myocardial tissue pathological section: the apical tissues were removed, fixed in 10% formaldehyde, HE stained, and the histomorphometry of each group of specimens was observed under a light microscope.
2.3 statistical treatment: using SPSS 13.0 software, data are expressed in x + -s, and the comparison between two groups using t-test, P <0.05 is statistically significant.
3 results
3.1 Effect on acute myocardial ischemia rat Electrocardiogram: after injecting Iso, as shown in table 1, T wave of the model group was increased and J point was shifted down compared with the control group, indicating myocardial ischemia; the SXK high dose significantly improved the J-point and T-wave amplitude of change (p <0.05) compared to the model group.
Table 1 effect of T-wave height and J-point height after isoproterenol injection (x ± s, n ═ 10)
Comparison with blank group▲P<0.05，▲▲P<0.01; comparison with model group■P<0.05，■■P<0.01。
3.2 Effect on serum GSH-Px, SOD, MDA: after injecting Iso, the GSH-Px and SOD activity in the rat serum is obviously reduced, and the MDA content is obviously increased. Compared with the model group, activities of GSH-Px and SOD in the serum of the rat of SXK three dose groups are increased to a certain degree, and MDA content is reduced, wherein, SXK high dose can obviously increase the activity of GSH-Px in the serum of the rat (p is less than 0.05), and can obviously reduce the MDA content in the serum of the rat (p is less than 0.05). See table 2.
TABLE 2 Effect on serum GSH-Px, MDA, SOD activity in rats with myocardial ischemia (x + -s, n ═ 10)
Comparison with blank group▲P<0.05，▲▲P<0.01; comparison with model group■P<0.05，■■P<0.01。
3.3 the myocardial cells of the rats in the blank group of the myocardial tissue pathological section are arranged orderly without obvious degeneration and necrosis and inflammatory cell infiltration in intercellular substance. Compared with a blank control group, the myocardial tissue of the model group has obvious ischemic injury, mainly presents myocardial fiber disorder, interstitial edema degeneration, myocardial cell vacuole degeneration, cytoplasm uneven staining, nucleus fixation shrinkage and other obvious pathological morphological structure changes, and indicates that the acute ischemic injury of the myocardium can be caused by the intraperitoneal injection of isoproterenol; compared with the model group, the myocardial necrosis area of each administration group is obviously reduced; the necrotic area of myocardial tissue decreased significantly with increasing doses, indicating SXK decreased the degenerative necrosis of myocardial cells, and the results are shown in FIG. 1.
The etiology of ischemic heart disease (coronary heart disease) is closely related to the generation of cardiac oxygen free radicals, myocardial hypoxia and ischemia induce oxidative stress reaction, a large number of neutrophils are gathered in an ischemic area to accelerate the generation of oxygen free radicals, and a large number of oxygen free radicals are accumulated to cause membrane lipid peroxidation to cause structural abnormality and functional damage of cell membranes, so that myocardial tissue damage is aggravated. Glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) are endogenous enzyme scavengers that counteract the oxidative destruction of free radicals, and Malondialdehyde (MDA) is a stable lipid peroxidated aldehyde acid product widely used to reflect oxidative stress levels. The high-dose composition SXK prepared by the invention has strong oxidation resistance, can improve the activity of GSH-Px and SOD in myocardial tissue, inhibit lipid peroxidation process, reduce the activity of lipid peroxide MDA, relieve the damage of oxygen free radical to myocardium, protect ischemic myocardium and treat ischemic heart disease.
In the research process, the rat can effectively inhibit myocardial tissue ischemia caused by Iso after being orally taken SXK, the height of T-wave and J-point is obviously changed, the activity of GSH-Px and SOD in serum is increased, the MDA content is obviously reduced, and the result shows that SXK can protect myocardial cells and improve the stability of cell membranes. It can be seen from the pathological section that after SXK is taken, the rat has great amount of inflammatory cell infiltration in the myocardial degeneration and necrosis area, disorganized and broken myocardial fiber arrangement, obviously improved myofilament melting and reduced pathological change range. Experiments prove that the traditional Chinese medicine composition SXK prepared by the invention can effectively inhibit myocardial tissue ischemia caused by isoproterenol (Iso) and protect myocardial cells from being damaged, thereby playing a role in treating coronary heart disease.
Claims (5)
1. A traditional Chinese medicine composition for myocardial ischemia is prepared from the following raw materials in parts by weight: 15 parts of fructus choerospondiatis, 10 parts of radix salviae miltiorrhizae, 10 parts of sandalwood, 10 parts of myrobalan and 10 parts of kapok.
2. A pharmaceutical preparation comprising the Chinese medicinal composition of claim 1.
3. The pharmaceutical formulation of claim 2, wherein the pharmaceutical formulation is a pill.
4. The use of the composition of claim 1 in the preparation of a medicament for treating myocardial ischemia.
5. The use of the composition of claim 1 for the preparation of a medicament for the treatment of coronary heart disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110543818.8A CN113244288B (en) | 2021-05-19 | 2021-05-19 | Traditional Chinese medicine composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110543818.8A CN113244288B (en) | 2021-05-19 | 2021-05-19 | Traditional Chinese medicine composition and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113244288A CN113244288A (en) | 2021-08-13 |
| CN113244288B true CN113244288B (en) | 2022-03-25 |
Family
ID=77182724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110543818.8A Active CN113244288B (en) | 2021-05-19 | 2021-05-19 | Traditional Chinese medicine composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113244288B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526353A (en) * | 2012-03-15 | 2012-07-04 | 山东阿如拉药物研究开发有限公司 | Method for preparing medicinal composition preparation for treating myocardial ischemia |
| CN103977336A (en) * | 2014-05-27 | 2014-08-13 | 石任兵 | Pharmaceutical composition with myocardial ischemia resisting effect and preparation method and application thereof |
-
2021
- 2021-05-19 CN CN202110543818.8A patent/CN113244288B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526353A (en) * | 2012-03-15 | 2012-07-04 | 山东阿如拉药物研究开发有限公司 | Method for preparing medicinal composition preparation for treating myocardial ischemia |
| CN103977336A (en) * | 2014-05-27 | 2014-08-13 | 石任兵 | Pharmaceutical composition with myocardial ischemia resisting effect and preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 复方舒心康对异丙肾上腺素所致大鼠急性心肌缺血的影响;于莹，等;《吉林中医药》;20220131;第42卷(第1期);第76-79页 * |
| 漫谈心脏疾病的饮食疗法;阳军;《药膳食疗研究》;19991231(第02期);第23页左栏第3段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113244288A (en) | 2021-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104225217B (en) | A kind of Chinese medicine preparation for treating coronary heart disease and preparation method thereof | |
| CN101347422B (en) | Uses of salvianolic acid A in preventing and/or treating diabetes and complication | |
| CN115120689A (en) | Application of Xinli rehabilitation formula preparation in preparation of medicines | |
| CN107496573B (en) | Application of houttuynia cordata extract in preparation of pharmaceutical preparation for preventing myocardial ischemia reperfusion injury | |
| CN103919854A (en) | Application of butterflybush flower and extract thereof to preparation of medicament | |
| CN113244288B (en) | Traditional Chinese medicine composition and application thereof | |
| CN113350396B (en) | Preparation method of traditional Chinese medicine composition for resisting myocardial ischemia | |
| CN102488779A (en) | Application of extract of Antlerpilose grass | |
| CN108567914A (en) | It is a kind of that there is the Chinese medicine preparation and its preparation method and application for improving sleep effect | |
| CN108570116B (en) | Pleurotus citrinopileatus polysaccharide, preparation method and medical application in preventing and treating diabetes | |
| CN113559144A (en) | Application of glycyrrhiza glabra crude extract in treating non-alcoholic fatty liver disease | |
| CN112915107A (en) | Application of periplaneta americana ethyl acetate extract in preparation of drugs and/or health products for resisting acute myeloid leukemia and products | |
| CN112007058A (en) | Application of oroxylum indicum as antioxidant stress injury agent | |
| CN111228323A (en) | Application of alcohol extract of pyrola in preparation of medicine for preventing and/or treating myocardial ischemic diseases | |
| CN105998752B (en) | A kind of Chinese medicine composition for the treatment of of vascular dementia | |
| CN101843669B (en) | Chinese medicinal effective-part composition for treating coronary heart diseases | |
| CN105535890B (en) | A kind of pharmaceutical composition and preparation method thereof for treating cardiovascular disease | |
| CN110693897B (en) | Application of oil tea flesh fruit polysaccharide in preparation of medicine or health-care product for preventing and treating type II diabetes | |
| CN114652740B (en) | Leonurine, polygonatum polysaccharide and deoxynojirimycin pharmaceutical composition and application thereof | |
| CN112716999B (en) | Preparation method of cinnamon extract, cinnamon extract and application of cinnamon extract | |
| CN1269488C (en) | Pharmaceutical composition capable of resisting cancer and easing pain | |
| CN111000886B (en) | Pharmaceutical composition for treating cerebral arterial thrombosis and application thereof | |
| CN106798826A (en) | Tuber of dwarf lilyturf oligosaccharides is preparing the application in promoting brown fat generation medicine | |
| CN116421676A (en) | Chinese medicinal composition for treating coronary heart disease and angina pectoris, and its preparation method | |
| CN111053796A (en) | Application of globe amaranth herb water extract in preparation of drug for treating acute liver injury of mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230721 Address after: Binxi economic and Technological Development Zone, Binxi Town, Binxian County, Harbin City, Heilongjiang Province Patentee after: HEILONGJIANG RUTAI TECHNOLOGY DEVELOPMENT Co.,Ltd. Address before: 150000 comprehensive building of Heilongjiang University of traditional Chinese medicine, No. 24 Heping Road, Xiangfang District, Harbin, Heilongjiang Province Patentee before: HEILONGJIANG University OF CHINESE MEDICINE |
|
| TR01 | Transfer of patent right |